Is Foracort 100 safe for an 11-year-old child weighing 24 kg?
Yes, Foracort (budesonide/formoterol) 100 µg is safe for an 11-year-old child weighing 24 kg when used appropriately for asthma control. This child falls within the 5-11 years age group for which budesonide/formoterol combination therapy has established safety and efficacy data.
Age-Appropriate Dosing and Safety Profile
For children aged 5-11 years with asthma, budesonide/formoterol is FDA-approved and guideline-supported 1. The typical dosing for this age group is 2 puffs twice daily, with the dose depending on asthma severity and control level 1. At 11 years old and 24 kg, this child is well within the appropriate age range, though slightly below average weight for age (which does not contraindicate use).
The safety profile in this age group is well-established 2, 3. A 26-week study of 187 children aged 6-11 years showed budesonide/formoterol was well-tolerated with similar adverse event rates (84.6%) to budesonide alone (85.7%), with most events being mild or moderate 2. Treatment-related adverse events were low (4.9%) and comparable to monotherapy 2.
Key Safety Considerations
Monitor growth velocity carefully. The 2007 NAEPP guidelines note that in low-to-medium doses, suppression of growth velocity has been observed in children, though this effect may be transient 1. One study showed yearly growth actually improved by 1.0 cm compared to higher-dose budesonide alone 4, but ongoing height monitoring remains prudent.
Common adverse effects to anticipate include tachycardia, skeletal muscle tremor, hypokalemia, headache, and hyperglycemia 1. Local effects like cough, dysphonia, and oral thrush can be minimized by using a spacer and having the child rinse and spit after inhalation 1.
Critical Safety Warnings
Never use as monotherapy for long-term control. LABAs (including formoterol) must always be combined with an inhaled corticosteroid 1. The combination product Foracort satisfies this requirement, but standalone LABA use increases the risk of asthma-related hospitalization in pediatric patients 5.
Not for acute symptom relief or exacerbations. Short-acting beta-agonists remain the treatment of choice for acute bronchospasm 1. The formoterol component provides bronchodilation, but this is a maintenance medication.
Dosing Specifics for This Child
Based on guideline recommendations 1:
- Low dose range: 180-400 mcg budesonide daily (for children 5-11 years)
- Medium dose range: >400-800 mcg budesonide daily
- Foracort 100 typically refers to budesonide 100 µg per actuation
If this is budesonide/formoterol 80/4.5 µg (2 inhalations = 160/9 µg twice daily), this falls within the low-dose ICS range and is appropriate for mild-to-moderate persistent asthma 3. If the formulation is 160/4.5 µg per 2 inhalations twice daily, this represents 320 µg budesonide daily—still within safe parameters for this age group 2, 3.
Practical Implementation
Ensure proper inhaler technique. Children in this age group can typically use a pressurized metered-dose inhaler (pMDI) with a spacer or valved holding chamber 1. Verify technique at each visit, as improper use reduces efficacy and increases local side effects.
Avoid CYP3A4 inhibitors. Budesonide is metabolized by CYP3A4 enzymes; potent inhibitors like ritonavir and ketoconazole can increase systemic exposure and risk of Cushing syndrome or adrenal suppression 1.
Titrate to the minimum effective dose. Once asthma control is achieved, step down therapy to the lowest dose that maintains control 1. This minimizes potential systemic effects while preserving efficacy.
Monitoring Parameters
- Height/growth velocity every 3-6 months
- Asthma control (symptoms, nighttime awakenings, rescue inhaler use)
- Pulmonary function (spirometry when feasible)
- Adverse effects (tremor, tachycardia, behavioral changes)
Common pitfall: Failing to assess and optimize inhaler technique leads to suboptimal drug delivery and poor control. Always demonstrate and observe the child's technique.
The combination of budesonide and formoterol in a single inhaler ensures adherence to both controller and bronchodilator components 5, which is particularly important in pediatric populations where separate inhalers often lead to ICS underuse.